regorafenib + vudalimab

Regorafenib + vudalimab is an investigational **combination therapy** under clinical evaluation for the treatment of advanced or metastatic solid tumors, including colorectal cancer. **Regorafenib** is a small molecule multi-kinase inhibitor targeting angiogenic (VEGFR1-3), oncogenic (KIT, RET, RAF), and stromal (PDGFR, FGFR, CSF1R) receptor tyrosine kinases, inhibiting tumor angiogenesis and proliferation. **Vudalimab** (XmAb20717) is a bispecific monoclonal antibody targeting **programmed cell death protein 1 (PD-1)** and **cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)**, functioning as a dual immune checkpoint inhibitor to potentiate T cell–mediated anti-tumor responses. The combination is being studied primarily in advanced **colorectal cancer**, including stage II–IV and metastatic setting, aiming to enhance immune checkpoint blockade and anti-angiogenic activity synergistically for improved clinical outcomes[3][6]. Regorafenib is developed and marketed by Bayer, whereas vudalimab is developed by Xencor.

Brand names

Stivarga (for regorafenib)

Other names

regorafenib + XmAb20717